The Experts below are selected from a list of 93516 Experts worldwide ranked by ideXlab platform

Ahmedin Jemal - One of the best experts on this subject based on the ideXlab platform.

  • international trends in Liver Cancer incidence rates
    Cancer Epidemiology Biomarkers & Prevention, 2011
    Co-Authors: Ahmedin Jemal
    Abstract:

    Background: Several previous studies have documented region or country-specific Liver Cancer incidence trends around the world. However, no study has systematically examined the international pattern using the most recently updated incidence data from the International Agency for Research on Cancer. Methods: We examined recent trends in Liver Cancer incidence rates from 1993 to 2002 by joinpoint analysis for 32 Cancer registries worldwide, using Cancer Incidence in Five Continents. We also examined the male to female rate ratios for these and four additional registries, based on the 1998–2002 incidence data. Results: Liver Cancer incidence rates for both men and women statistically significantly increased from 1993 to 2002 for 8 of 32 Cancer registries considered in the analysis. Increases were largely confined to economically developed countries of Western Europe, North America, and Oceania. In contrast, rates decreased in both men and women in 5 registries including 3 in Asia. Despite this, the incidence rates in Asian countries are twice as high as those in Africa and more than four times as high as rates in North America. Male to female rate ratios varied from 0.9 in sub-Saharan African and South American registries to 5.0 in France and Egypt. Conclusions: Liver Cancer incidence rates continue to increase in some low-risk parts of the world whereas they are decreasing in some of the highest risk countries in Asia. Etiologic studies are required to further elucidate factors contributing to the divergent Liver Cancer incidence trends worldwide. Impact: Our description of international Liver Cancer incidence trends may stimulate further etiologic studies. Cancer Epidemiol Biomarkers Prev; 20(11); 2362–8. ©2011 AACR . This article is featured in Highlights of This Issue, [p. 2329][1] [1]: /lookup/volpage/20/2329?iss=11

Rui Zhang - One of the best experts on this subject based on the ideXlab platform.

  • Liver Cancer CT Image Segmentation Methods Based on Watershed Algorithm
    2009 International Conference on Computational Intelligence and Software Engineering, 2009
    Co-Authors: Zhongyi Wang, Rui Zhang
    Abstract:

    To achieve a effective segmentation for Liver Cancer CT image, this paper utilizes comprehensive the edge detection, the watershed algorithm and region merging approach, propose a segmentation method of Liver Cancer CT image based on the watershed algorithm, gain a better effect in the course of Liver Cancer CT image segmentation, and solve effectively the over-segmentation phenomenon of the traditional method, get closed, continuous, more accurate lesion region contour. The experimental results show that the method can be used to achieve better Liver Cancer CT image lesions region segmentation.

  • Contour Correction Liver Cancer CT Image Segmentation Method Based on Snake Model
    2009 2nd International Congress on Image and Signal Processing, 2009
    Co-Authors: Rui Zhang, Jianwei Wang
    Abstract:

    To segment CT (computed tomography) images of Liver Cancer effectively, a new method based on Snake model was proposed. Image segmentation based on threshold was combined with image segmentation based on Snake model, and a contour correction process was added. This method obtains a better result on Liver Cancer CT images segmentation, overcomes the defect that traditional Snake model can not segment the images with serious depressions. The results of the experiment demonstrate that this algorithm is an effective method for segmenting the Liver Cancer image.

Ramon Cleries - One of the best experts on this subject based on the ideXlab platform.

  • primary Liver Cancer worldwide incidence and trends
    Gastroenterology, 2004
    Co-Authors: Xavier F Bosch, Josepa Ribes, Mireia Diaz, Ramon Cleries
    Abstract:

    Estimates from the year 2000 indicate that Liver Cancer remains the fifth most common malignancy in men and the eighth in women worldwide. The number of new cases is estimated to be 564,000 per year, including 398,000 in men and 166,000 in women. In high-risk countries, Liver Cancer can arise before the age of 20 years, whereas, in countries at low risk, Liver Cancer is rare before the age of 50 years. Rates of Liver Cancer in men are typically 2 to 4 times higher than in women. The incidence of primary Liver Cancer is increasing in several developed countries, including the United States, and the increase will likely continue for some decades. The trend is a result of a cohort effect related to infection with hepatitis B and C viruses, the incidence of which peaked in the 1950s to 1980s. In selected areas of some developing countries, the incidence of primary Liver Cancer has decreased, possibly as a result of the introduction of hepatitis B virus vaccine. The geographic variability in incidence of primary Liver Cancer is largely explained by the distribution and the natural history of the hepatitis B and C viruses. The attributable risk estimates for the combined effects of these infections account for well over 80% of Liver Cancer cases worldwide. Primary Liver Cancer is the first human Cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses.

Jianwei Wang - One of the best experts on this subject based on the ideXlab platform.

  • Expression of IL-13Rα2 in Liver Cancer cells and its effect on targeted therapy of Liver Cancer
    Journal of Cancer Research and Clinical Oncology, 2009
    Co-Authors: Juan Du, Jianwei Wang, Yanpeng Zheng, Li-shu Zhang, Honggang Hu, Weijun Guan
    Abstract:

    Purpose Liver Cancer is the third leading cause of Cancer-related deaths globally. The number of Liver Cancers diagnosed in the world is increasing at an alarming rate. It is of great significance to find the new targets of the tumor cells and specific medicine. This research investigated the expression of interleukin-13 receptor α2 (IL-13Rα2) in different Liver Cancer cell lines and Liver Cancer tissues, and assessed the cytotoxin DT389-hIL13-13E13K (IL-13 and diphtheria toxin fusion protein) targeted killing effect on Liver Cancer cells. Based on study above, we further analyzed the function of IL-13Rα2 on the targeted Liver Cancer therapy. The results will provide a novel strategy and an alternative way for Liver Cancer therapy.

  • Contour Correction Liver Cancer CT Image Segmentation Method Based on Snake Model
    2009 2nd International Congress on Image and Signal Processing, 2009
    Co-Authors: Rui Zhang, Jianwei Wang
    Abstract:

    To segment CT (computed tomography) images of Liver Cancer effectively, a new method based on Snake model was proposed. Image segmentation based on threshold was combined with image segmentation based on Snake model, and a contour correction process was added. This method obtains a better result on Liver Cancer CT images segmentation, overcomes the defect that traditional Snake model can not segment the images with serious depressions. The results of the experiment demonstrate that this algorithm is an effective method for segmenting the Liver Cancer image.

G Zhang - One of the best experts on this subject based on the ideXlab platform.

  • Correlations of ultrasonic features with severity of Liver Cancer and p16 expression in patients with Liver Cancer.
    Neoplasma, 2019
    Co-Authors: Q Xiao, G Zhang
    Abstract:

    : This paper analyzes the correlations of ultrasonic features with clinical-pathological manifestations and p16 expression in patients with Liver Cancer. A total of 84 patients with primary Liver Cancer were randomly enrolled. The characteristics of Liver Cancer were examined via conventional ultrasound and contrast-enhanced ultrasound (CEUS) before operation. The p16 protein expressions in Liver Cancer and para-carcinoma tissues were detected via immunohistochemistry (IHC), and the correlations of p16 positive expression with ultrasound parameters were also analyzed. It was manifested via ultrasound that 6.4% (3/47) of stage I-II Liver Cancer showed the equal-echo change in portal phase, while others faded and showed the equal-echo change with 32.4% (12/37) of stage III-IV Liver Cancer. There were no statistically significant differences in ultrasonic features of patients in stage I-II and stage III-IV in the arterial and delayed phases (p>0.05). The positive expression rate of p16 protein in para-carcinoma tissues was 85.71% (72/84) which was significantly higher than that in Liver Cancer tissues (30.95%, 26/84) (p 0.05), but it positively correlated with RS (correlation coefficient r=0.377, p

  • Correlations of ultrasonic features with severity of Liver Cancer and p16 expression in patients with Liver Cancer.
    Neoplasma, 2018
    Co-Authors: Q Xiao, G Zhang
    Abstract:

    This paper analyzes the correlations of ultrasonic features with clinical-pathological manifestations and p16 expression in patients with Liver Cancer. A total of 84 patients with primary Liver Cancer were randomly enrolled. The characteristics of Liver Cancer were examined via conventional ultrasound and contrast-enhanced ultrasound (CEUS) before operation. The p16 protein expressions in Liver Cancer and para-carcinoma tissues were detected via immunohistochemistry (IHC), and the correlations of p16 positive expression with ultrasound parameters were also analyzed. It was manifested via ultrasound that 6.4% (3/47) of stage I-II Liver Cancer showed the equal-echo change in portal phase, while others faded and showed the equal-echo change with 32.4% (12/37) of stage III-IV Liver Cancer. There were no statistically significant differences in ultrasonic features of patients in stage I-II and stage III-IV in the arterial and delayed phases (p>0.05). The positive expression rate of p16 protein in para-carcinoma tissues was 85.71% (72/84) which was significantly higher than that in Liver Cancer tissues (30.95%, 26/84) (p